If you have been reading about Tesamorelin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
The biliary tract is derived from the branches of the bile ducts. The biliary tract, also known as the biliary tree, is the path by which bile is secreted by the liver then transported to the first part of the small intestine, the duodenum. The bile produced in the liver is collected in bile canaliculi, small grooves between the faces of adjacent hepatocytes. The canaliculi radiate to the edge of the liver lobule, where they merge to form bile ducts. Within the liver, these ducts are termed intrahepatic bile ducts, and once they exit the liver, they are considered extrahepatic. The intrahepatic ducts eventually drain into the right and left hepatic ducts, which exit the liver at the transverse fissure, and merge to form the common hepatic duct. The cystic duct from the gallbladder joins with the common hepatic duct to form the common bile duct. The biliary system and connective tissue is supplied by the hepatic artery alone. Bile either drains directly into the duodenum via the common bile duct, or is temporarily stored in the gallbladder via the cystic duct. The common bile duct and the pancreatic duct enter the second part of the duodenum together at the hepatopancreatic ampulla, also known as the ampulla of Vater.
is the ideal gas constant. The relationships between the state variables described in this equation are a good approximation of the behavior of many gases under a wide range of conditions, though there are some limitations.
Current evidence suggests that dinosaur average size varied through the Triassic, Early Jurassic, Late Jurassic and Cretaceous. Predatory theropod dinosaurs, which occupied most terrestrial carnivore niches during the Mesozoic, most often fall into the 100-to-1,000 kg (220-to-2,200 lb) category when sorted by estimated weight into categories based on order of magnitude, whereas recent predatory carnivoran mammals peak in the 10-to-100 kg (22-to-220 lb) category. The mode of Mesozoic dinosaur body masses is between 1 and 10 metric tons (1.1 and 11.0 short tons). This contrasts sharply with the average size of Cenozoic mammals, estimated by the National Museum of Natural History as about 2 to 5 kg (4.4 to 11.0 lb). The sauropods were the largest and heaviest dinosaurs. For much of the dinosaur era, the smallest sauropods were larger than anything else in their habitat, and the largest was an order of magnitude more massive than anything else that has since walked the Earth. Giant prehistoric mammals such as Paraceratherium (the largest land mammal ever) were dwarfed by the giant sauropods, and only modern whales approach or surpass them in size. There are several proposed advantages for the large size of sauropods, including protection from predation, reduction of energy use, and longevity, but it may be that the most important advantage was dietary. Large animals are more efficient at digestion than small animals, because food spends more time in their digestive systems. This also permits them to subsist on food with lower nutritive value than smaller animals.
Following Geoffrey Howe's resignation speech in November 1990, Heseltine challenged Thatcher for the party leadership, polling well enough to deny her an outright victory on the first ballot. Following Thatcher's subsequent resignation, Heseltine lost to Major on the second ballot, but returned to the Cabinet in his former post of Environment Secretary when Major became prime minister. As a key ally of Major, Heseltine was appointed President of the Board of Trade and Secretary of State for Trade and Industry following the 1992 general election. He supported Major when his leadership was challenged in 1995, and was promoted to Deputy Prime Minister and First Secretary of State. He declined to seek the leadership of the party following Major's 1997 election defeat, and served in Major's shadow cabinet as Deputy Leader of the Opposition, Shadow Chancellor of the Duchy of Lancaster and Shadow Secretary of State for Trade and Industry while the leadership election to succeed him was taking place. Heseltine was created a life peer in 2001 and has remained a vocal advocate of modernisation within the party. He has continued to make political interventions, criticising Brexit and Boris Johnson following the 2016 Brexit referendum result. In 2019, Heseltine had the whip suspended after saying he would vote for the Liberal Democrats, rather than the Conservatives, at the 2019 European Parliament election. Heseltine had the whip restored in July 2024.
=== Tau in Frontotemporal Lobar Degeneration (FTLD) === The tau protein is one of the most common aggregated proteins in frontotemporal lobar degeneration (FTLD), the pathology underlying FTD disorders, the other being TDP-43. While protein aggregation underlies FTLD tauopathies, the specific tau isoforms present and the morphology of the aggregates vary across subtypes. FTLD tauopathies are predominantly associated with the 3R and 4R tau isoforms. The “Pick bodies” characteristic of the FTLD tauopathy known as “Pick’s disease” is associated with 3R tau. Progressive supranuclear palsy (PSP) and corticobasal syndrome/degeneration (CBS/CBD), meanwhile, are associated with the 4R isoform. There is evidence that a ratio of 3R and 4R tau is essential for preventing neurodegeneration, and that alterations in this ratio are believed to drive FTLD and related disorders without requiring co-occurrence with other pathologies. FTD-tau appears to be sporadic in the majority of people diagnosed, but researchers do not yet fully understand the pathological mechanisms. Inherited pathogenic variants in the MAPT gene, however, are responsible for a fraction of people diagnosed with FTD-tau. Within and between families, FTD due to MAPT presents with significant heterogeneity in the symptoms that may be present, underscoring the possibility for genetic modifiers and environmental factors to influence clinical presentation. Intronic variants in MAPT, and most variants in exon 10, affect the 3R/4R tau ratio, contributing significantly to the development of FTLD pathology.
Sources: en.wikipedia.org
W.E.S. Turner; F. Winks (1926). Journal of the Society of Glass Technology. 102. {{cite journal}}: Missing or empty |title= (help) F. Janowski; W. Heyer (1982). Poröse Gläser – Herstellung, Eigenschaften und Anwendungen. VEB Deutscher Verlag für Grundstoffindustrie, Leipzig. F. Friedel (2001). Diplomarbeit, Halle. {{cite book}}: Missing or empty |title= (help) F. Janowski (1993). Maschinenmarkt. 99: 28–33. {{cite journal}}: Missing or empty |title= (help) O.S. Moltschanowa (1957). Glas und Keramik. 14: 5–7. {{cite journal}}: Missing or empty |title= (help) F. Wolf; W. Heyer (1968). "Modifizierte poröse gläser als träger in der gaschromatographie". J. Chromatogr. 35: 489–496. doi:10.1016/s0021-9673(01)82414-6. Schuller GmbH (1999). "Life Sciences – Mehr als nur poröse Gläser (Anwenderbericht)". LABO9: 26–28. SCHOTT Information. 53. 1990. {{cite journal}}: Missing or empty |title= (help) M. Hermann (VitraBio GmbH) (2007). "Verfahren zur Herstellung eines porösen Glases und Glaspulvers und Glaswerkstoff zum Ausführen des Verfahrens". WO 098778. {{cite journal}}: Cite journal requires |journal= (help) P. W. McMillan; C. E. Matthews (1976). "Microporous glasses for reverse osmosis". J. Mater. Sci. 11 (7): 1187–1199. Bibcode:1976JMatS..11.1187M. doi:10.1007/bf00545135. S2CID 137379816. F. Janowski; A. Sophianos; F. Wolf (1979). "The role of acidity of MoO3−SiO2 and WO3−SiO2 catalysts". React. Kinet. Catal. Lett. 12 (2): 443. doi:10.1007/BF02071904. S2CID 102283765. G.R. Gavalas; C.E. Megiris; S.W. Nam (1989). "Deposition of H2-permselective SiO2 films". Chem. Eng. Sci.
Directed by Bob Bee, produced by Michael Wills, made by Juniper Productions 5 September Fatal Protein, looking at the cause of CJD in humans, BSE in cattle, and scrapie in sheep; BSE was killing 1,000 British cattle a week; a brain disorders conference in Jamaica; in Papua New Guinea, the disease was called kuru or 'the laughing death', first found in the Okapa District in early 1950s by Carlton Gadjusek; Australian Michael Alpers took an interest in 1960s, at the Institute of Medical Research; epidemiologist Paul Brown of the National Institutes of Health; chimpanzees were tested on, and one suffered from ataxia; GSS, discovered in Austria, was similar, and found in Indiana; Martin Farlow, of the Indiana University Medical Center; most research was carried out on mice and hamsters; Stanley B.
Another prospective cohort study on a sample of 79 coronary patients spanning in excess of 12 years found improved metrics of physical endurance, circadian rhythm, and carbohydrate and lipid metabolism in the treated group relative to the control group following 3 years of biannual epithalamin treatments, as well as a 50% lower rate of cardiovascular mortality, a 50% lower rate of cardiovascular failure and serious respiratory disease, and a 28% lower rate of overall mortality.
Avicenna discouraged opium's use except as a last resort, preferring to address the causes of pain rather than trying to minimize it with analgesics. Many of Avicenna's observations have been supported by modern medical research. Exactly when the world became aware of opium in India and China is uncertain, but opium was mentioned in the Chinese medical work Kaibao Bencao (973 AD) By 1590 AD, opium poppies were a staple spring crop in the Subahs of Agra region. The physician Paracelsus (c. 1493–1541) is often credited with reintroducing opium into medical use in Western Europe, during the German Renaissance. He extolled opium's benefits for medical use. He also claimed to have an "arcanum", a pill which he called laudanum, that was superior to all others, particularly when death was to be cheated. ("Ich hab' ein Arcanum – heiss' ich Laudanum, ist über das Alles, wo es zum Tode reichen will.") Later writers have asserted that Paracelsus' recipe for laudanum contained opium, but its composition remains unknown.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.